Oral Session

Oral Session 1-10B Treatment of MM: Immunomodulatory drugs etc

Fri. Oct 12, 2018 10:10 AM - 11:10 AM No.10 (Osaka International Convention Center, 10F 1009)

Chair: Reiko Nakaseko (Saitama medical center. Saitama Medical University, Japan)

+Add all to schedule

[OS1-10B-1] Elotuzumab plus lenalidomide/dexamethasone prolongs survival duration of RRMM patients

Yutaka Okuno¹, Yawara Kawano¹, Shikiko Ueno¹, Hiroyuki Hata², Masao Matsuoka¹ (1.Departments of Hematology, Kumamoto University Graduate School of Medicine, 2.Division of Informative Clinical Sciences, Kumamoto University)

[OS1-10B-2] Efficacy of lenalidomide + new drugs after pomalidomide treatment

Mitsuhiro Itagaki, Hideki Asaoku, Yuta Katayama, Tatsuya Terasaki, Yu Kochi, Fumiaki Jinnouchi, Tatsuji Mino, Takeshi Okatani, Ryota Imanaka, Kohei Kyo, Shinya Katsutani, Tsuyoshi Muta, Koji Iwato (Dept.Hematology Hiroshima Red Cross Hospital, Hiroshima, Japan)

[OS1-10B-3] Analysis of the long-term effective cases of pomalidomide in patients with R/R MM in our hospital

Raine Tatara, Kanako Yoshitsugu, Masafumi Fukaya, Ikue Shiki, Terukazu Enami, Takashi Ikeda (Hematology, Shizuoka Cancer Center Hospital, Nagaizumi-cho, Japan)

[OS1-10B-4] Retrospective analysis of bortezomib, lenalidomide and dexamethasone for NDMM -second report-

Tadao Ishida, Nobuhiro Tsukada, Kota Sato, Kanji Miyazaki, Yumiko Yoshiki, Yu Abe, Kiyoshi Okazuka, Kenshi Suzuki (Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan)

[OS1-10B-5] Survival of patients with multiple myeloma that is refractory to both bortezomib and lenalidomide

Kanji Miyazaki, Kota Sato, Yumiko Yoshiki, Yu Abe, Kiyoshi Okazuka, Nobuhiro Tsukada, Tadao Ishida, Kenshi Suzuki (Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan)

[OS1-10B-6] KRD and KD treatment for relapsed/refractory multiple myeloma in Kansai Myeloma Forum study

Yoshiyuki Onda¹, Junya Kanda¹, Hitomi Kaneko², Hirohiko Shibayama³, Yuji Shimura⁴, Kensuke Ohta⁵, Hirokazu Tanaka⁶, Shin-Ichi Fuchida⁷, Aya Nakaya⁸, Nobuhiko Uoshima⁹, Satoru Kosugi¹⁰, Mitsuhiro Matsuda¹¹, Yoko Adachi¹², Hideo Yagi¹³, Hitoji Uchiyama¹⁴, Maki Shindo¹, Kazunori Imada², Masayuki Hino¹⁵, Shosaku Nomura¹⁶, Chihiro Shimazaki⁷, Junya Kuroda⁴, Yuzuru Kanakura³, Akifumi Takaori-Kondo¹, Itaru Matsumura⁶ (1.Hematol. and Oncol., Kyoto Univ., Kyoto, Japan, 2.Hematol., Japanese Red Cross Osaka Hospital, Osaka, Japan, 3.Hematol. and Oncol., Osaka Univ.,Osaka, Japan, 4.Hematol. and Oncol., Kyoto Prefectural Univ. of Medicine, Kyoto, Japan, 5.Hematol., Osaka Saiseikai Nakatsu Hospital, Osaka, Japan, 6.Hematol. and Rheumatol., Kinki Univ., Osaka, Japan, 7.Hematol., JCHO Kyoto Kuramaguchi Medical Center, Kyoto, Japan, 8.Hematol., Kansai Medical Univ. Medical Center, Osaka, Japan, 9.Hematol., Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan, 10.Internal Medicine (Hematol.), Toyonaka Municipal Hospital, Osaka, Japan, 11.Hematol., PL General Hospital, Osaka, Japan, 12.Internal Medicine, JCHO Kobe Central Hospital, Hyogo, Japan, 13.Hematol. and Oncol., Nara Prefecture General Medical Center, Nara, Japan, 14.Hematol., Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan, 15.Hematol., Osaka City Univ. Osaka, Japan, 16.First Department of Internal Medicine, Kansai Medical Univ.,Osaka, Japan)